Revive Therapeutics Ltd. RVVTF

Full chart Compare

Set alert

0.01 USD 0.00 (+0.00%)

At closeNov 4, 2026, 4:00 PM EST

0.0146 Day range 0.0146

0.002 52-week range 0.059

YTD: +75.00%
1 year: +55.56%

News

1 month ago accessnewswire.com Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programs TORONTO, ON / ACCESS Newswire / September 15,…
2 months ago accessnewswire.com Revive Therapeutics Announces Proposed Shares for Debt Settlement TORONTO, ON / ACCESS Newswire / August 19, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and…
2 months ago accessnewswire.com Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio Positive DRDC findings support the next phase for bucillamine as Revive plans to pursue government-backed development opportunities, expand intellectual property and evaluate complementary…
2 months ago accessnewswire.com Revive Therapeutics Reports Grant of Options TORONTO, ON / ACCESS Newswire / August 14, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and…
2 months ago accessnewswire.com Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study TORONTO, ON / ACCESS Newswire / August 12, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and…
3 months ago accessnewswire.com Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / July 15, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company")…
4 months ago accessnewswire.com Revive Therapeutics Announces Proposed Private Placement NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / June 26, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company")…
5 months ago accessnewswire.com Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious diseases, nerve-agent exposure, future…
7 months ago accessnewswire.com Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications TORONTO, ON / ACCESS Newswire / March 11,…
10 months ago globenewswire.com Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research…
11 months ago globenewswire.com Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research…
1 year ago globenewswire.com Revive Therapeutics Announces Closing of Second Tranche of Private Placement TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing…
1 year ago globenewswire.com Revive Therapeutics Announces Extension of Proposed Private Placement TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd.
1 year ago globenewswire.com Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing…
1 year ago globenewswire.com Revive Therapeutics Announces Proposed Private Placement and Debt Settlement TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing…
1 year ago globenewswire.com Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the…
1 year ago globenewswire.com Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research…
1 year ago globenewswire.com Revive Therapeutics Advances with Next-Generation Bucillamine Development TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing…
1 year ago globenewswire.com Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and…
1 year ago globenewswire.com Revive Therapeutics Announces Proposed Shares for Debt Transaction TORONTO, April 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research…
3 years ago benzinga.com GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today GAINERS: GH Research (NASDAQ: GHRS) shares closed up 6.63% at $11.74
6 years ago benzinga.com Stocks That Hit 52-Week Highs On Tuesday
7 years ago benzinga.com Stocks That Hit 52-Week Lows On Monday